
Charles River Laboratories
CRL · NYSE · Life Sciences Tools & Services
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $16,2 bn
- Div. yield
- —
- Year to date
- +69,4%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
4 ✓ · 1 — · 4 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 403,0 | 31,3 | 37,9 |
| Forward P/E | 29,5 | — | 29,5 |
| PEG | n/a | — | 3,7 |
| P/S | 4,1 | 2,5 | 6,6 |
| EV/EBITDA | 82,1 | 22,3 | 29,9 |
| P/FCF | 39,1 | — | 38,7 |
| P/B | 5,0 | 3,3 | 5,4 |
Industry median — across 11 profitable companies in “Life Sciences Tools & Services” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 22 analysts
- Buy
- 17
- Hold
- 5
- Sell
- 0
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 3,00 | 3,09 | Up +2,9% |
| Q2 2026 | 2,76 | 3,02 | Up +9,2% |
| Q1 2026 | 1,96 | 2,06 | Up +5,0% |
| Q4 2025 | 2,37 | 2,39 | Up +1,0% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 983 m | 1,00 bn | 996 m | 994 m | 1,00 bn | 1,03 bn | 984 m | 1,00 bn | 1,01 bn | 1,03 bn | 1,01 bn | 1,01 bn |
| EPS | 6,86 | −0,03 | −0,30 | −5,56 | 1,10 | 1,06 | 0,50 | −4,17 | 1,33 | 1,74 | 1,30 | 3,64 |
| Margin | 34,0% | −0,1% | −1,5% | −27,8% | 5,5% | 5,1% | 2,6% | −21,3% | 7,0% | 9,2% | 7,4% | 18,6% |
| FCF | 207 m | 149 m | −14,8 m | 58,6 m | 178 m | 169 m | 112 m | 83,7 m | 213 m | 154 m | 50,7 m | 143 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: purchases $7 338 (2 people), sales $52,1 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| foster james c22 Oct 2026 · sale | $8,41 m | 24 042 | $350,00 |
| parisotto shannon m21 Oct 2026 · sale | $742 548 | 2 156 | $344,41 |
| parisotto shannon m5 Oct 2026 · sale | $302 580 | 981 | $308,44 |
| coleman glenn30 Sep 2026 · open-market purchase | $2 974 | 10 | $297,43 |
| foster james c25 Aug 2026 · sale | $10,1 m | 33 561 | $300,00 |
| parisotto shannon m19 Aug 2026 · sale | $599 711 | 2 039 | $294,12 |
| andrews nancy c18 Aug 2026 · sale | $163 443 | 573 | $285,24 |
| girshick birgit11 Aug 2026 · sale | $1,82 m | 6 500 | $279,90 |
| parisotto shannon m11 Aug 2026 · sale | $1,04 m | 3 714 | $279,66 |
| foster james c10 Aug 2026 · sale | $7,90 m | 28 733 | $275,00 |
| knell michael gunnar6 Aug 2026 · sale | $190 278 | 736 | $258,53 |
| knell michael gunnar6 Aug 2026 · sale | $311 529 | 1 205 | $258,53 |
| knell michael gunnar6 Aug 2026 · sale | $104 446 | 404 | $258,53 |
| knell michael gunnar6 Aug 2026 · sale | $127 812 | 482 | $265,17 |
| knell michael gunnar6 Aug 2026 · sale | $163 643 | 620 | $263,94 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Life Sciences Tools & Services
- Exchange
- NYSE
- Country
- US
- IPO date
- 23 Jun 2000
- Website
- www.criver.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
RVTYRevvity | $148,85 | 56★★★★★★★★would watch | 68,1 | +4,6% | 8,6% |
TECHBio-Techne | $72,79 | 69★★★★★★★★★would watch | 62,9 | +0,9% | — |
WSTWest Pharmaceutical Services | $417,80 | 83★★★★★★★★★would consider | 45,5 | +12,6% | 18,8% |
ILMNIllumina, Inc. | $198,00 | 75★★★★★★★★★would consider | 33,6 | +5,8% | 19,7% |
MTDMettler Toledo | $1 727,26 | 63★★★★★★★★would watch | 36,5 | +6,5% | 22,2% |
Ratio — a score by our methodology, not an investment recommendation.




